<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01828346</url>
  </required_header>
  <id_info>
    <org_study_id>TL32711-0087</org_study_id>
    <nct_id>NCT01828346</nct_id>
  </id_info>
  <brief_title>Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy</brief_title>
  <official_title>A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TetraLogic Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TetraLogic Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose escalation followed by dose expansion study of TL32711 in combination with&#xD;
      5-Azacitidine in subjects with Myelodysplastic syndrome who are naïve, have relapsed or have&#xD;
      failed prior 5-azacitidine therapy. Pre-clinical and mechanistic studies support that&#xD;
      5-Azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2a, open-label, non-randomized study in male and female subjects with MDS&#xD;
      who are naïve, refractory or have relapsed to 5-Azacitidine therapy.&#xD;
&#xD;
      Primary Objective is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose,&#xD;
      and pharmacodynamics (PD) of birinapant (TL32711) when administered in combination with&#xD;
      5-azacitidine (5 AZA) in subjects with myelodysplastic syndrome (MDS) who are naïve,&#xD;
      refractory or have relapsed to 5-AZA therapy.&#xD;
&#xD;
      Secondary Objectives are to determine the clinical activity using the International Working&#xD;
      Group (IWG) (Cheson, 2006) Response Criteria for MDS during the Phase 1b dose escalation&#xD;
      stage of the study and in the Phase 2a expansion cohort, to determine the pharmacokinetics&#xD;
      (PK) of birinapant when administered with 5-AZA in plasma and to assess exploratory&#xD;
      translational biomarkers of anti-tumor activity of birinapant in combination therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-Azacitidine plus birinapant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Birinapant</intervention_name>
    <description>Dose escalation part: (Drug escalation dose levels)&#xD;
Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)&#xD;
Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)&#xD;
Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)&#xD;
Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR&#xD;
Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>TL32711</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Azacitidine</intervention_name>
    <description>Dose Level (0) - 75mg/m2 daily</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>5-AZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women more than 18 years of age.&#xD;
&#xD;
          -  Patients with high-risk Myelodysplastic Syndrome&#xD;
&#xD;
          -  Performance status of greater or equal to 2 by the Eastern Cooperative Oncology Group&#xD;
             (ECOG) scale.&#xD;
&#xD;
          -  Subjects with high-risk MDS who are naïve to 5-Azacitidine or have previously received&#xD;
             5-AZA or decitabine as first-line cytotoxic therapy. Subjects with prior 5-Azacitidine&#xD;
             therapy were evaluated to be either refractory or relapsed as determined by the&#xD;
             Investigator, according to IWG response criteria.Subjects with relapsed or refractory&#xD;
             disease may have only received prior 5-Azacitidine or decitabine.&#xD;
&#xD;
          -  Hydroxyurea for patients with rapidly proliferative disease can be used up to 24 hours&#xD;
             prior to therapy but not concomitantly with 5-Azacitidine.&#xD;
&#xD;
          -  Adequate liver, pancreatic and renal function.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test at screening&#xD;
             within 48 hours prior to the first dose&#xD;
&#xD;
          -  Women of childbearing potential must agree to use 2 methods of adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with life-threatening toxicity or non tolerability to prior 5-Azacitidine&#xD;
             therapy.&#xD;
&#xD;
          -  Subjects with hypoplastic Myelodysplastic syndrome.&#xD;
&#xD;
          -  Subjects with &gt;30% bone marrow blast cells.&#xD;
&#xD;
          -  Subjects with malignant hepatic tumors or secondary malignancy within 2 years&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus or chronic active Hepatitis B or C.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications,&#xD;
&#xD;
          -  QT interval corrected for heart rate (QTcB) more than 480 msec&#xD;
&#xD;
          -  Lack of recovery of prior adverse events to Grade ≤1 severity (National Cancer&#xD;
             Institute Common Terminology Criteria for Adverse Events version 4) (except alopecia)&#xD;
             due to therapy administered prior to the initiation of study drug dosing.&#xD;
&#xD;
          -  Nursing or pregnant women.&#xD;
&#xD;
          -  Known allergy to any of the formulation components of birinapant.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to 5-Azacitidine or mannitol.&#xD;
&#xD;
          -  Any concurrent disease and/or medical condition that, in the opinion of the&#xD;
             Investigator, would prevent the subject's participation.&#xD;
&#xD;
          -  History of Bell's Palsy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Verde Hematology Oncology</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2013</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TL32711</keyword>
  <keyword>Birinapant</keyword>
  <keyword>5-Azacitidine</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Failed</keyword>
  <keyword>open-label</keyword>
  <keyword>non-Randomized</keyword>
  <keyword>dose-escalation</keyword>
  <keyword>dose-expansion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

